Analysts Back Solventum (SOLV) as Consistent Execution Reinforces Growth Outlook

Solventum Corporation (NYSE:SOLV) is one of the most undervalued and overlooked large-cap stocks. On August 8, analysts from Piper Sandler raised their price target on Solventum Corporation (NYSE:SOLV) to $94 from $87, while maintaining an Overweight rating. The adjustment followed Q2 results that showed revenue of $2.16 billion, up 2.8% organically, and EPS of $1.69, both ahead of consensus.

The analysts observed that Solventum Corporation (NYSE:SOLV) is steadily building a record of reliable execution, a key factor behind its recent upgrade. The latest quarterly results strengthened that view, as performance came in ahead of expectations and reinforced confidence in management’s ability to meet its guidance.

Earlier on August 8, Stifel Nicolaus analyst Rick Wise reaffirmed his confidence in Solventum Corporation (NYSE:SOLV) with a Buy rating and an unchanged price target of $88.

Solventum Corporation (NYSE:SOLV) develops healthcare products, including health information systems, purification and filtration technologies, and consumables.

While we acknowledge the potential of SOLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Stocks to Buy and Hold Forever and 12 Overlooked Large-Cap Stocks with Low Multiples.

Disclosure: None. This article is originally published at Insider Monkey.